Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action
Open Access
- 18 June 2021
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-18
Abstract
The receptor tyrosine kinase HER2 acts as oncogenic driver in numerous cancers. Usually, the gene is amplified, resulting in receptor overexpression, massively increased signaling and unchecked proliferation. However, tumors become frequently addicted to oncogenes and hence are druggable by targeted interventions. Here, we design an anti-HER2 biparatopic and tetravalent IgG fusion with a multimodal mechanism of action. The molecule first induces HER2 clustering into inactive complexes, evidenced by reduced mobility of surface HER2. However, in contrast to our earlier binders based on DARPins, clusters of HER2 are thereafter robustly internalized and quantitatively degraded. This multimodal mechanism of action is found only in few of the tetravalent constructs investigated, which must target specific epitopes on HER2 in a defined geometric arrangement. The inhibitory effect of our antibody as single agent surpasses the combination of trastuzumab and pertuzumab as well as its parental mAbs in vitro and it is effective in a xenograft model.Keywords
This publication has 57 references indexed in Scilit:
- Fiji: an open-source platform for biological-image analysisNature Methods, 2012
- Camera: a competitive gene set test accounting for inter-gene correlationNucleic Acids Research, 2012
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinaseProceedings of the National Academy of Sciences of the United States of America, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recyclingProceedings of the National Academy of Sciences, 2010
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- Structural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell, 2005
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complexCancer Cell, 2004
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003